Archives: Agenda

• Understanding patient expectations when a treatment shows clear benefit during a trial
• Managing continuation pathways once a study ends and the therapy is not yet commercially available
• Exploring where sponsors, sites, and physicians struggle to align on responsibility and feasibility

• Baselining the magnitude of China Biotech & Pharma
• Understanding the shift for the broader industry
• Reflecting on China market realities
• Implications for agencies, contractors, and vendors
• The way out

• Moving beyond transactional outsourcing toward integrated partnership models​
• Mitigating operational unpredictability with clear governance, escalation,​ and proactive engagement​
• How CROs differentiate through delivery consistency and functional expertise

• Exploring how regulatory and economic shifts disrupt timelines
• Supporting teams to adapt while protecting patient access
• Strengthening readiness for rapid pivots in study delivery

Moderator:

Mary MacDonald, Director, Clinical Quality Assurance, Eisai

• Exploring lessons from shifting between outsourcing models
• Supporting clearer expectations between sponsors and CROs
• Strengthening RBQM alignment across portfolios

• Exploring community-based research solutions — particularly mobile visits — beyond simple procedural support, toward a more holistic, human-centered approach
• Demonstrating how mobile research clinicians deliver far more than sample collection, bringing diverse skilled clinician types directly to patients’ homes and communities to perform complex protocol activities
• Highlighting how expanded clinical capability strengthens trust, enhances patient experience and drives high-quality data collection, reinforcing human presence as a key differentiator in an increasingly technology-driven research environment

• Defining clear roles between sponsors and vendors in hybrid models to avoid overlap
• Facilitating seamless exchange of operational metrics and risk indicators across vendors ensuring proactive oversight and responsive decisions
• Implementing risk-based oversight to focus on what matters most eliminating redundancies while enhancing quality
• Designing governance frameworks that accelerate decision making while ensuring continuous inspection readiness

• Understand when oversight creates real value versus when it’s just a checkbox
• Hear what vendors wish sponsors would stop doing (and vice versa)
• Explore 3 key pillars of oversight: relationship management, performance management, and quality & compliance
• Learn how industry leaders are navigating the hardest parts of risk-based oversight: scalability, regulatory complexity, and the resource-intensive nature of the work
• Walk away with practical insights you can apply to your own oversight plan — whether you’re building one from scratch or maturing an existing program

Moderator: Peter Haessig, Head of Client Partnerships, Diligent Pharma